Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

1.02
-0.0400-3.77%
Post-market: 1.020.00000.00%19:30 EDT
Volume:138.63K
Turnover:142.45K
Market Cap:27.19M
PE:-3.57
High:1.08
Open:1.07
Low:1.02
Close:1.06
52wk High:3.40
52wk Low:0.7069
Shares:26.65M
Float Shares:21.83M
Volume Ratio:1.48
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.3933
ROE:-69.86%
ROA:-22.85%
PB:2.64
PE(LYR):-2.59

Loading ...

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

GlobeNewswire
·
Sep 23

Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth

TradingKey
·
Sep 23

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

MT Newswires Live
·
Sep 22

Alkermes data show measurable improvements in ADHD, says H.C. Wainwright

TIPRANKS
·
Sep 22

Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target

TIPRANKS
·
Sep 21

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live
·
Sep 21

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

TIPRANKS
·
Sep 21

Helus Pharma presents new analyses on HLP003 in MDD

TIPRANKS
·
Sep 21

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

TIPRANKS
·
Sep 21

Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback

TIPRANKS
·
Sep 15

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

TIPRANKS
·
Sep 10

Analyst Reiterates Buy on Definium Therapeutics, Maintains $75 Price Target Following De-Risking of DT120 ODT in MDD and GAD

TIPRANKS
·
Sep 09

Mizuho survey shows no consensus into Alkermes ADHD data

TIPRANKS
·
Sep 05

Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In

Simply Wall St.
·
Sep 02

Blinklab Showcases AI Smartphone Platform for Autism and ADHD Diagnosis

TIPRANKS
·
Sep 01

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

GlobeNewswire
·
Aug 31

Lilly’s Brenipatide Steps Into Phase 3: A New Long-Term Play in Depression Care

TIPRANKS
·
Aug 28

ABVC BioPharma Completes BioKey Cayman Spin-Off Transaction

TIPRANKS
·
Aug 27

ABVC Biopharma Completes BioKey Cayman Spinoff, Distributes 15% Stake to Shareholders

Reuters
·
Aug 27

Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Dow Jones
·
Aug 13